Convergent Fortifies Leadership for Radiopharma Growth Spurt

CAMBRIDGE, Mass. – January 28, 2026 – Convergent Therapeutics, a clinical-stage biotechnology company at the forefront of radiopharmaceutical development, has appointed Elizabeth L. Montgomery as its new Chief People Officer. The move signals a strategic pivot from pure research and development toward building a robust organization capable of navigating late-stage clinical trials and potential commercialization for its promising cancer therapies.

Montgomery, who joins the executive leadership team this month, steps into a role that is becoming increasingly critical for biotechs on the cusp of significant expansion. Her appointment comes as Convergent prepares to advance its lead candidate, CONV01-α, into pivotal Phase 3 studies for metastatic castration-resistant prostate cancer (mCRPC), a milestone that necessitates a rapid and strategic scaling of the company's talent and infrastructure.

The Human Capital Imperative in Late-Stage Biotech

For a company like Convergent, moving a novel drug into Phase 3 trials is a monumental undertaking that extends far beyond the laboratory. It requires a significant expansion of clinical operations, regulatory affairs, and manufacturing capabilities. The appointment of an experienced CPO underscores a recognition that human capital strategy is as vital as the science itself at this inflection point.

Montgomery brings over two decades of experience in organizational design and talent development within the life sciences sector. Her recent tenure as CPO at Black Diamond Therapeutics, a precision oncology firm, and previously at ClearView Healthcare Partners, a global life sciences strategy consultancy, provides her with a deep understanding of the unique challenges of scaling specialized teams.

“Elizabeth is a proven leader with deep experience scaling organizations, building high-performing teams, and guiding leadership through periods of transformation,” said Philip Kantoff, MD, CEO and co-Founder of Convergent Therapeutics. “As we advance our pipeline and prepare for our next phase of growth, her expertise will be essential as we build the infrastructure to support our Phase 3 studies of CONV01-α in metastatic castration-resistant prostate cancer and continue scaling our radioantibody pipeline.”

The challenge is not merely hiring more people, but attracting and retaining a highly specialized workforce. Experts in radiochemistry, nuclear medicine, clinical trial management for radioligands, and regulatory submissions for radioactive drugs are in high demand. Montgomery’s role will be central to crafting a value proposition that attracts this top-tier talent in a fiercely competitive market.

A Pipeline Poised for a Breakthrough

The driving force behind Convergent's organizational build-out is the immense promise of its pipeline, led by CONV01-α. This next-generation therapy is a radioantibody that targets the prostate-specific membrane antigen (PSMA), a protein heavily expressed on the surface of prostate cancer cells.

What sets CONV01-α apart is its payload: actinium-225 (Ac-225), a potent alpha-emitting radioisotope. Unlike beta emitters used in some existing therapies, alpha particles deliver a powerful, highly localized dose of radiation. They travel a very short distance—only a few cell diameters—before releasing their energy, causing lethal double-strand DNA breaks in cancer cells while largely sparing surrounding healthy tissue. This precision has the potential to offer greater efficacy with a more favorable safety profile, particularly reducing toxicities like dry mouth that can be associated with other PSMA-targeted agents.

The company's confidence is supported by compelling clinical data. In a Phase 1 trial combining CONV01-α with another radioligand therapy, the treatment demonstrated a median overall survival of nearly 30 months in mCRPC patients, an outcome that significantly surpasses results from pivotal trials of current standard-of-care radiotherapies. Following the FDA's clearance of its Investigational New Drug (IND) application in 2024, Convergent initiated its company-sponsored Phase 2 CONVERGE-01 trial, with the first patient dosed in September 2024. The company is now rapidly moving toward initiating its pivotal Phase 3 program.

“I’m excited to join Convergent at such an important stage of growth and to support its mission to advance novel treatments for patients with prostate cancer,” Ms. Montgomery stated. “Convergent is built on world-class science, innovation, and clinical excellence, and I look forward to partnering with leadership and the broader team as we enter the company’s next phase of evolution.”

Navigating a Competitive Radiopharmaceutical Landscape

Convergent’s strategic hiring comes amidst a period of intense activity and investment in the radiopharmaceutical sector. The field of targeted radiotherapy, particularly using alpha emitters, is considered one of the most exciting frontiers in modern oncology. This has led to a land rush for both technology and talent.

Recent blockbuster acquisitions, such as Bristol Myers Squibb's purchase of RayzeBio and AstraZeneca's acquisition of Fusion Pharmaceuticals, have sent a clear signal: major pharmaceutical players see immense value and potential in this space. This M&A activity has supercharged the market, placing immense pressure on clinical-stage companies like Convergent to compete for the limited pool of experienced scientists, clinicians, and executives.

By bringing in a CPO with Montgomery's track record, Convergent is making a proactive move to solidify its position as an employer of choice. Building a strong corporate culture, offering competitive compensation, and providing a clear vision for growth are essential tools in this talent war. The ability to effectively recruit and integrate teams will be a key differentiator as the company works to establish CONV01-α as potentially the first Ac-225-based radioantibody approved for prostate cancer.

Building on a Foundation of Strong Investment

Underpinning this strategic expansion is a solid financial foundation. Convergent has successfully secured $130 million in Series A financing, a testament to strong investor confidence in its technology and strategy. The funding rounds were led by premier life sciences investors, including OrbiMed, RA Capital Management, and a recent extension from Novo Holdings.

This substantial capital allows the company to not only fund its ambitious clinical development plans for CONV01-α but also to invest in the organizational infrastructure necessary for success. The hiring of a CPO is a direct application of these resources, aimed at ensuring that the company’s human capital scales in lockstep with its clinical and corporate ambitions. With funding secured and a seasoned people leader now on board, Convergent appears well-equipped to manage the complexities of late-stage development and prepare for its transition into a commercial-stage entity.

The move to fortify its leadership team is a clear indication that Convergent is looking beyond the science, focusing on building a durable enterprise capable of delivering its innovative therapies from the lab to patients in need.